- Home
- FFNW vs ACRV Comparison
FFNW vs ACRV Comparison
Compare FFNW & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFNW
- ACRV
- Stock Information
- Founded
- FFNW 1923
- ACRV 2018
- Country
- FFNW United States
- ACRV United States
- Employees
- FFNW N/A
- ACRV N/A
- Industry
- FFNW Banks
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- FFNW Finance
- ACRV Health Care
- Exchange
- FFNW Nasdaq
- ACRV Nasdaq
- Market Cap
- FFNW 203.8M
- ACRV 203.9M
- IPO Year
- FFNW N/A
- ACRV 2022
- Fundamental
- Price
- FFNW $21.30
- ACRV $6.60
- Analyst Decision
- FFNW Hold
- ACRV Strong Buy
- Analyst Count
- FFNW 3
- ACRV 5
- Target Price
- FFNW $23.00
- ACRV $22.40
- AVG Volume (30 Days)
- FFNW 32.1K
- ACRV 63.0K
- Earning Date
- FFNW 01-23-2025
- ACRV 11-13-2024
- Dividend Yield
- FFNW 1.22%
- ACRV N/A
- EPS Growth
- FFNW N/A
- ACRV N/A
- EPS
- FFNW 0.12
- ACRV N/A
- Revenue
- FFNW $37,168,000.00
- ACRV N/A
- Revenue This Year
- FFNW N/A
- ACRV N/A
- Revenue Next Year
- FFNW $2.64
- ACRV N/A
- P/E Ratio
- FFNW $183.94
- ACRV N/A
- Revenue Growth
- FFNW N/A
- ACRV N/A
- 52 Week Low
- FFNW $13.16
- ACRV $3.19
- 52 Week High
- FFNW $23.50
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- FFNW 27.22
- ACRV 42.20
- Support Level
- FFNW $21.18
- ACRV $6.56
- Resistance Level
- FFNW $22.18
- ACRV $7.45
- Average True Range (ATR)
- FFNW 0.35
- ACRV 0.47
- MACD
- FFNW -0.12
- ACRV -0.00
- Stochastic Oscillator
- FFNW 10.32
- ACRV 28.12
About FFNW First Financial Northwest Inc.
First Financial Northwest Inc is the holding company. The Bank's business consists predominantly of attracting deposits from the general public, combined with borrowing from the FHLB of Des Moines and raising funds in the wholesale market then utilizing these funds to originate one-to-four family residential, multifamily, commercial real estate, construction/land, business, and consumer loans. The Bank's strategic initiatives seek to diversify its loan portfolio and broaden growth opportunities with its current risk tolerance levels and asset/liability objectives.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.